Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis

被引：8
|
作者：
Christopher, Karen L. [1 ]
Elner, Victor M. [1 ]
Demirci, Hakan [1 ]
机构：
[1] Univ Michigan, Dept Ophthalmol & Visual Sci, WK Kellogg Eye Ctr, 1000 Wall St, Ann Arbor, MI 48109 USA
来源：
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY | 2017年 / 33卷 / 03期
关键词：
B-CELL LYMPHOMA; RITUXIMAB;
D O I：
10.1097/IOP.0000000000000774
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
The authors describe a 39-year-old woman treated with fingolimod for relapsing-remitting multiple sclerosis for 2 years who then developed a bilateral conjunctival mucosa-associated lymphoid tissue lymphoma. Fingolimod treatment for multiple sclerosis has been associated with lymphoma in 3 previously reported cases. This is the first case of ocular adnexal lymphoma presumed to be due to fingolimod. Given that ophthalmologists regularly monitor many patients on fingolimod for fingolimod-associated macular edema and ophthalmic manifestations of multiple sclerosis, the authors hope to alert physicians of the possibility of ocular adnexal lymphoma in these patients.
引用
收藏
页码：E73 / E75
页数：3
相关论文
共 50 条
  • [1] Fingolimod for relapsing-remitting multiple sclerosis
    La Mantia, Loredana
    Tramacere, Irene
    Firwana, Belal
    Pacchetti, Ilaria
    Palumbo, Roberto
    Filippini, Graziella
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (04):
  • [2] Oral fingolimod for relapsing-remitting multiple sclerosis
    Doggrell, Sheila A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (10) : 1777 - 1781
  • [3] Kaposi sarcoma in a patient with relapsing-remitting multiple sclerosis receiving fingolimod
    Tully, Timothy
    Barkley, Alastair
    Silber, Eli
    NEUROLOGY, 2015, 84 (19) : 1999 - 2001
  • [4] Effects of fingolimod in relapsing-remitting multiple sclerosis Comment
    Sorensen, Per Soelberg
    LANCET NEUROLOGY, 2014, 13 (06): : 526 - 527
  • [5] ORAL FINGOLIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Vosiliou, S.
    DRUGS OF TODAY, 2010, 46 (05) : 315 - 325
  • [6] Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis
    Chacko, Joseph A.
    Strati, Paolo
    Stout, Paul W.
    Archer, Robert L.
    Baltz, Brad P.
    Chacko, Joseph G.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 49
  • [7] Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod
    Calvi, Alberto
    De Riz, Milena
    Lecchi, Elisabetta
    Pietroboni, Anna
    Ghezzi, Laura
    Scarioni, Marta
    Carandini, Tiziana
    Galimberti, Daniela
    Scarpini, Elio
    Pellegrinelli, Alessandro
    Maurichi, Andrea
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 296 - 297
  • [8] Fingolimod-induced asthma deterioration in a patient with relapsing-remitting multiple sclerosis
    van Rossum, J. A.
    Looysen, E. E.
    Daniels, J. M. A.
    Killestein, J.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (13) : 1792 - 1793
  • [9] Pharmacogenomic predictors of fingolimod response in relapsing-remitting multiple sclerosis
    Campagna, M. P.
    Stankovich, J.
    Zhong, M.
    Kleinova, P.
    Matesanz, F.
    Eichau, S.
    Slee, M.
    Kilpatrick, T.
    Kubala Havrdova, E.
    Izquierdo, G.
    Patsopoulos, N.
    Lea, R.
    Lechner-Scott, J.
    Butzkueven, H.
    Jokubaitis, V.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 660 - 661
  • [10] Fingolimod: A Review of Its Use in Relapsing-Remitting Multiple Sclerosis
    Mark Sanford
    Drugs, 2014, 74 : 1411 - 1433
12345